News Focus
News Focus
icon url

Guzzi62

11/15/25 3:39 AM

#508295 RE: Investor2014 #508293

Sadly, it seems like you are right, he has really destroyed it for patients, investors and the company he is running.

I hope he will be re-placed very soon, he is too focused on having money in the bank instead of running proper trials.

Will a BP be interested in a partnership now, I wonder? They can get things moving fast.
Maybe they are not very interested with Missling at the rudder?
If that's the case, another good reason for him to pack his bags and move back to Germany.
icon url

WolfofMia

11/15/25 5:26 AM

#508296 RE: Investor2014 #508293

Yea Dr.M why would you leave the company without debt lol
icon url

frrol

11/15/25 8:25 AM

#508303 RE: Investor2014 #508293

Let's see what Monday brings. Like trial results, this is the kind of development that really needs a thorough and frank explanation to investors. Missling is inclined to spin, so others like Talavera, Sabbagh, or Grimmer should join. Jin would also be great, particularly if there were data issues or analysis disagreements.

Missling will hopefully be replaced. If 2-73 is a viable drug, we shouldn't be sitting here in 2025 with no trials and no approvals. He ultimately failed, and made pretty foolish mistakes along the way. Better would be selling the company to a large pharma with stronger management and adequate capital.